PepGen Inc Dossier - Source-backed chat

PepGen Inc

PEPGNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.54

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.21Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $153.1M

Shares Outstanding 78.7M diluted

Next Earnings Date11 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

PepGen Inc. is a clinical-stage biotechnology company utilizing its proprietary Enhanced Delivery Oligonucleotide (EDO) platform to optimize tissue delivery of therapeutic oligonucleotides. Following the strategic discontinuation of its Duchenne muscular dystrophy (DMD) candidate PGN-EDO51 in May 2025 due to insufficient efficacy, PepGen has consolidated its resources on its lead program, PGN-EDODM1, for myotonic dystrophy type 1 (DM1). While the program faces a partial clinical hold in the US due to preclinical mouse toxicology findings, clinical trials continue uninterrupted in Canada, the UK, and South Korea. Topline data from the fully enrolled 10 mg/kg MAD cohort of the FREEDOM2 trial is expected in the second half of 2026, representing a major near-term catalyst. Backed by a solid cash position of $132.3 million as of Q1 2026, which funds operations into the second half of 2027, PepGen offers a high-risk, high-reward opportunity in the targeted RNA therapeutics space.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$10.25

High · most bullish analyst$20.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$3.0020%

The FDA partial clinical hold is not resolved, or similar safety concerns (such as transient kidney biomarker elevations or blood pressure drops) emerge in human trials. The 10 mg/kg cohort data fails to show competitive splicing correction compared to emerging competitors like Avidity Biosciences or Dyne Therapeutics, leading to further pipeline delays and cash burn.

Base CaseCentral scenario

$9.2550%

The FREEDOM2 trial continues to progress in ex-US geographies. The 10 mg/kg MAD cohort readout in 2H 2026 confirms therapeutic activity with meaningful splicing correction and manageable safety. The FDA hold resolution takes longer but does not block the overall global development timeline. The stock recovers steadily as clinical milestones are met.

Bull CaseUpside scenario

$15.0030%

The FDA lifts the partial clinical hold on the FREEDOM2 trial after reviewing clinical safety data, allowing US site activation. The 10 mg/kg MAD cohort data in 2H 2026 demonstrates robust, dose-dependent splicing correction (exceeding 50%) and a clean safety profile, positioning PGN-EDODM1 as a best-in-class therapy for DM1. The stock experiences a significant re-rating toward historical highs.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary EDO platform designed to overcome the historical challenge of delivering oligonucleotides to muscle tissue.
Consolidated focus on PGN-EDODM1 for DM1, a high unmet need indication with a large addressable market.
FREEDOM2 10 mg/kg MAD cohort is fully enrolled, ensuring on-track data readout in 2H 2026.
Strong liquidity with $132.3 million in cash and marketable securities, providing runway into 2H 2027.

Key Investment Risks

Regulatory risk highlighted by the active FDA partial clinical hold on the FREEDOM2 trial in the US.
Clinical execution risk, particularly following the previous discontinuation of the DMD program (PGN-EDO51) for lack of efficacy.
Intense competition from well-capitalized peers such as Avidity Biosciences and Dyne Therapeutics advancing clinical-stage DM1 programs.

Thesis Invalidation Triggers

Failure of the 10 mg/kg MAD cohort of PGN-EDODM1 to show meaningful splicing correction in the 2H 2026 readout.
Inability to resolve the FDA partial clinical hold, permanently blocking US clinical development.
Emergence of severe, dose-limiting toxicities (e.g., renal or cardiovascular) in ongoing clinical cohorts.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.